The TGFβ-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors

Cancer Research

Volumn 74, Issue 14, 2014, Pages 3995-4005

  Izumchenko, Evgeny ^a   Chang, Xiaofei ^a   Michailidi, Christina ^a   Kagohara, Luciane ^a   Ravi, Rajani ^a   Paz, Keren ^b   Brait, Mariana ^a   Hoque, Mohammad ^a   Ling, Shizhang ^a   Bedi, Atul ^a   Sidransky, David ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Champions Oncology Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FOCAL ADHESION KINASE; MESSENGER RNA; MICRORNA 200; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA 205; PROTEIN KINASE B; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR ZEB1; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA3; UVOMORULIN; VIMENTIN;

3' UNTRANSLATED REGION; ARTICLE; CANCER CELL LINE; CANCER RESISTANCE; CELL VIABILITY; CELLULAR, SUBCELLULAR AND MOLECULAR BIOLOGICAL PHENOMENA AND FUNCTIONS; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIAL MESENCHYMAL TRANSITION ASSOCIATED KINASE SWITCH; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; LUNG CANCER; MITOGEN INDUCIBLE GENE 6; MOLECULAR DYNAMICS; PANCREAS CANCER; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; UPREGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICE; MICRORNAS; ORGAN SPECIFICITY; PANCREATIC NEOPLASMS; PHENOTYPE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904265894     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0110     Document Type: Article

References (42)

1. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39. (Pubitemid 38637993)
2. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
3. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-44. (Pubitemid 41058345)
4. Lemos-Gonzalez Y, Paez de la Cadena M, Rodriguez-Berrocal FJ, Rodriguez-Pineiro AM, Pallas E, Valverde D. Absence of activating mutations in the EGFR kinase domain in Spanish head and neck cancer patients. Tumour Biol 2007;28:273-9. (Pubitemid 350165833)
5. Tzeng CW, Frolov A, Frolova N, Jhala NC, Howard JH, BuchsbaumDJ, et al. Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. Surgery 2007;141:464-9. (Pubitemid 46441307)
6. van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MC, Kros JM, Carpentier AF, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 2009;27:1268-74.
7. Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L, et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 2005;11:8686-98. (Pubitemid 43005918)
8. Thomson S, Petti F, Sujka-Kwok I, Epstein D, Haley JD. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin Exp Metastasis 2008;25:843-54.
9. Thomson S, Buck E, Petti F, Grif fin G, Brown E, Ramnarine N, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 2005;65: 9455-62. (Pubitemid 41508014)
10. Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, et al. miR200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 2009;15:5060-72.
11. Barr S, Thomson S, Buck E, Russo S, Petti F, Sujka-Kwok I, et al. Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal- like transitions. Clin Exp Metastasis 2008;25:685-93.
12. Massague J. TGFbeta signalling in context. Nat Rev Mol Cell Biol 2012;13:616-30.
13. Vincent T, Neve EP, Johnson JR, Kukalev A, Rojo F, Albanell J, et al. A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta- mediated epithelial-mesenchymal transition. Nat Cell Biol 2009; 11:943-50.
14. Ozdamar B, Bose R, Barrios-Rodiles M, Wang HR, Zhang Y, Wrana JL. Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity. Science 2005;307:1603-9. (Pubitemid 40354739)
15. Samavarchi-Tehrani P, Golipour A, David L, Sung HK, Beyer TA, Datti A, et al. Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming. Cell Stem Cell 2010;7:64-77.
16. Korpal M, Lee ES, Hu G, Kang Y. The miR200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008;283:14910-4.
17. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR200 family and miR205 regulate epithelial-to-mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10:593- 601.
18. Tryndyak VP, Beland FA, Pogribny IP. E-cadherin transcriptional downregulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer 2010;126:2575-83.
19. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, et al. A reciprocal repression between ZEB1 and members of the miR200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008;9:582-9. (Pubitemid 351772923)
20. Fiorentino L, Pertica C, Fiorini M, Talora C, Crescenzi M, Castellani L, et al. Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain. Mol Cell Biol 2000;20:7735-50.
21. Hackel PO, Gishizky M, Ullrich A. Mig6 is a negative regulator of the epidermal growth factor receptor signal. Biol Chem 2001;382: 1649- 62.
22. Anastasi S, Fiorentino L, Fiorini M, Fraioli R, Sala G, Castellani L, et al. Feedback inhibition by RALT controls signal output by the ErbB network. Oncogene 2003;22:4221-34. (Pubitemid 36876243)
23. Zhang X, Pickin KA, Bose R, Jura N, Cole PA, Kuriyan J. Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature 2007;450:741-4. (Pubitemid 350207680)
24. Chang X, Izumchenko E, Solis LM, Kim MS, Chatterjee A, Ling S, et al. The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors. PLoS ONE 8:e68966.
25. Ferby I, Reschke M, Kudlacek O, Knyazev P, Pante G, Amann K, et al. Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation. Nat Med 2006;12:568-73.
26. Harsha HC, Jimeno A, Molina H, Mihalas AB, Goggins MG, Hruban RH, et al. Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy. J Proteome Res 2008;7:4651-8.
27. Jimeno A, Tan AC, Coffa J, Rajeshkumar NV, Kulesza P, Rubio- Viqueira B, et al. Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. Cancer Res 2008;68:2841-9. (Pubitemid 351556283)
28. Fiorini M, Ballaro C, Sala G, Falcone G, Alema S, Segatto O. Expression of RALT, a feedback inhibitor of ErbB receptors, is subjected to an integrated transcriptional and posttranslational control. Oncogene 2002;21:6530-9. (Pubitemid 35155457)
29. Nakamura K, Yano H, Schaefer E, Sabe H. Different modes and qualities of tyrosine phosphorylation of Fak and Pyk2 during epithelial- mesenchymal transdifferentiation and cell migration: analysis of specific phosphorylation events using site-directed antibodies. Oncogene 2001;20:2626-35. (Pubitemid 32525293)
30. Cicchini C, Laudadio I, Citarella F, Corazzari M, Steindler C, Conigliaro A, et al. TGFbeta-induced EMT requires focal adhesion kinase (FAK) signaling. Exp Cell Res 2008;314:143-52. (Pubitemid 350180782)
31. Bedi A, Chang X, Noonan K, Pham V, Bedi R, Fertig EJ, et al. Inhibition of TGF-beta enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy. Mol Cancer Ther 2012;11:2429-39.
32. Gregory PA, Bracken CP, Smith E, Bert AG, Wright JA, Roslan S, et al. An autocrine TGF-beta/ZEB/miR200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell 2011;22:1686-98.
33. Xu Q, Wang L, Li H, Han Q, Li J, Qu X, et al. Mesenchymal stem cells play a potential role in regulating the establishment and maintenance of epithelial-mesenchymal transition in MCF7 human breast cancer cells by paracrine and induced autocrine TGF-beta. Int J Oncol 2012;41: 959-68.
34. Bryant JL, Britson J, Balko JM, Willian M, Timmons R, Frolov A, et al. A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT. Br J Cancer 2012;106: 148-56.
35. Ceppi P, Mudduluru G, Kumarswamy R, Rapa I, Scagliotti GV, Papotti M, et al. Loss of miR200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res 2010;8:1207-16.
36. Derynck R, Goeddel DV, Ullrich A, Gutterman JU, Williams RD, Bringman TS, et al. Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res 1987;47:707-12. (Pubitemid 17027960)
37. Dickson RB, Kasid A, Huff KK, Bates SE, Knabbe C, Bronzert D, et al. Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17 beta-estradiol or v-Ha-ras oncogene. Proc Natl Acad Sci U S A 1987;84:837 -41.
38. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial-to-mesenchymal transition. Cell Res 2009;19:156-72.
39. Nieto MA. The ins and outs of the epithelial-to-mesenchymal transition in health and disease. Ann |Rev Cell Dev Biol 2011;27:347-76.
40. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-90.
41. Brabletz S, Brabletz T. The ZEB/miR200 feedback loop-a motor of cellular plasticity in development and cancer? EMBO Rep 2010;11: 670-7.
42. Wang SE, Xiang B, Guix M, Olivares MG, Parker J, Chung CH, et al. Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol Cell Biol 2008;28: 5605-20.